Advertisement
Advertisement
September 7, 2016
Veniti Closes on Equity Financing From Boston Scientific
September 8, 2016—Veniti, Inc. has closed on $25 million in a Series D equity financing deal from Boston Scientific Corporation. Veniti is a developer of treatments for deep venous disease. The funds will allow the company to complete the VIRTUS trial and regulatory filing for the Vici venous stent system. Veniti also intends to expand product development and commercial operations.
The VIRTUS trial is being performed under a US Food and Drug Administration investigational device exemption.
According to the company, Veniti’s Vici venous stent and Vici Verto venous stent were developed for the challenges of treating iliofemoral venous outflow obstruction. The Vici venous stent system was designed to provide physicians with a balance of crush resistance, flexibility, and ease of deployment.
The devices have received CE Mark approval and are commercially available in Europe. The Vici venous stent is approved by the Australian Therapeutic Goods Administration and is commercially available in Australia. The Vici stent is limited by law to investigational use. The Vici Verto is not approved for sale in the United States.
Veniti was founded in 2010 and is headquartered in St. Louis, Missouri, with technical operations in Fremont, California.
Advertisement
Advertisement
